A Multicenter, Double-Masked, Parallel-Group, Vehicle-Controlled Study to Assess the Efficacy and Safety of RX-10045 Nanomicellar Ophthalmic Solution for Treatment of Ocular Inflammation and Pain in Subjects Undergoing Cataract Surgery

The primary objective of this study is to assess the efficacy and safety of 2 concentrations of RX-10045 ophthalmic solution, 0.05% and 0.1%, compared to placebo for the treatment of ocular inflammation and pain in subjects undergoing cataract surgery.

Start Date01 Dec 2014

Sponsor / Collaborator

A.T. Resolve SARL

NCT01675570 / CompletedPhase 2

A Phase II, Multi-Center, Randomized, Placebo-Controlled, Double-Masked Study of RX-10045 (0.09%) in the Treatment of Dry Eye Disease

The primary purpose of this study is to assess the efficacy, tolerability and safety of RX-10045 Ophthalmic Solution in patients with Dry Eye Disease.

Start Date01 Aug 2012

Sponsor / Collaborator

C.T. Development America, Inc.

NCT01639846 / CompletedPhase 2

A Single-Center, Double-Masked, Randomized, Vehicle Controlled Evaluation of the Onset and Duration of Action of RX-10045 Ophthalmic Solution, 0.09% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC) Model of Allergic Conjunctivitis

To purpose of this study is to establish the efficacy and safety of RX-10045 ophthalmic solution in alleviating the signs and symptoms of allergic conjunctivitis

Start Date01 Jul 2012

Sponsor / Collaborator

C.T. Development America, Inc.

100 Clinical Results associated with Chemerin receptors x Lipid

100 Translational Medicine associated with Chemerin receptors x Lipid

0 Patents (Medical) associated with Chemerin receptors x Lipid

Literatures (Medical) associated with Chemerin receptors x Lipid

01 Dec 2018·Journal of Cellular PhysiologyQ2 · BIOLOGY

Exercise activates the hypothalamic S1PR1–STAT3 axis through the central action of interleukin 6 in mice

Q2 · BIOLOGY

Article

Author: de Lima‐Júnior, José C. ; Silva, Vagner R. R. ; Passos, Gabriela R. ; da Silva, Adelino S. R. ; Gaspar, Rodrigo S. ; Velloso, Licio A. ; Cintra, Dennys E. ; Micheletti, Thayana O. ; Moura‐Assis, Alexandre ; Saad, Mario J. ; Pauli, José R. ; Morari, Joseane ; Moura, Leandro P. ; Lenhare, Luciene ; Camargo, Juliana A. ; Katashima, Carlos K. ; Ropelle, Eduardo R.

Hypothalamic sphingosine‐1‐phosphate receptor 1 (S1PR1), the G protein–coupled receptor 1 of sphingosine‐1‐phosphate, has been described as a modulator in the control of energy homeostasis in rodents. However, this mechanism is still unclear. Here, we evaluate the role of interleukin 6 (IL‐6) associated with acute physical exercise in the control of the hypothalamic S1PR1–signal transducer and activator of transcription 3 (STAT3) axis. Acute exercise session and an intracerebroventricular IL‐6 injection increased S1PR1 protein content and STAT3 phosphorylation in the hypothalamus of lean and obese mice accompanied by a reduction in food consumption. Transcriptome analysis indicated a strong positive correlation between Il‐6 and S1pr1 messenger RNA in several tissues of genetically diverse BXD mice strains and humans, including in the hypothalamus. Interestingly, exercise failed to stimulate the S1PR1–STAT3 axis in IL‐6 knockout mice and the disruption of hypothalamic‐specific IL‐6 action blocked the anorexigenic effects of exercise. Taken together, our results indicate that physical exercise modulates the S1PR1 protein content in the hypothalamus, through the central action of IL‐6.

01 Apr 2008·Journal of Clinical InvestigationQ1 · MEDICINE

A CD28 superagonistic antibody elicits 2 functionally distinct waves of T cell activation in rats

Q1 · MEDICINE

Article

Author: Denise Tischner ; Judith Herath ; Holger M. Reichardt ; Alexander Flügel ; Jens van den Brandt ; Francesca Odoardi ; Nora Müller

Administration of the CD28 superagonistic antibody JJ316 is an efficient means to treat autoimmune diseases in rats, but the humanized antibody TGN1412 caused devastating side effects in healthy volunteers during a clinical trial. Here we show that JJ316 treatment of rats induced a dramatic redistribution of T lymphocytes from the periphery to the secondary lymphoid organs, resulting in severe T lymphopenia. Live imaging of secondary lymphoid organs revealed that JJ316 administration almost instantaneously (<2 minutes) arrested T cells in situ. This reduction in T cell motility was accompanied by profound cytoskeletal rearrangements and increased cell size. In addition, surface expression of lymphocyte function-associated antigen-1 was enhanced, endothelial differentiation sphingolipid G protein-coupled receptor 1 and L selectin levels were downregulated, and the cells lost their responsiveness to sphingosine 1-phosphate-directed migration. These proadhesive alterations were accompanied by signs of strong activation, including upregulation of CD25, CD69, CD134, and proinflammatory mediators. However, this did not lead to a cytokine storm similar to the clinical trial. While most of the early changes disappeared within 48 hours, we observed that CD4+CD25+FoxP3+ regulatory T cells experienced a second phase of activation, which resulted in massive cell enlargement, extensive polarization, and increased motility. These data suggest that CD28 superagonists elicit 2 qualitatively distinct waves of activation.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis